The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

Authors: Xinan Qiao, Jun Ma, Tristan Knight, Yongwei Su, Holly Edwards, Lisa Polin, Jing Li, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jian Wang, Hai Lin, Yue Wang, Liping Wang, Guan Wang, Jeffrey W. Taub & Yubin Ge

Citation: Qiao, X., Ma, J., Knight, T. et al. The combination of CUDC-907 and gilteritinb shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer J. (2021). https://doi.org/10.1038/s41408-021-00502-7

Used in this study: immunodeficient B-NDG mice